EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Beta Drugs's enterprise value is ₹11,264 Mil.
Beta Drugs's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ₹2,957 Mil. Therefore, Beta Drugs's EV-to-Revenue for today is 3.81.
The historical rank and industry rank for Beta Drugs's EV-to-Revenue or its related term are showing as below:
NSE:BETA'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.67 Med: 2.66 Max: 6.39
Current: 3.81
During the past 12 years, the highest EV-to-Revenue of Beta Drugs was 6.39. The lowest was 0.67. And the median was 2.66.
NSE:BETA's EV-to-Revenue is ranked worse than 69.31% of 1023
companies
in the Drug Manufacturers industry
Industry Median: 2.26
vs NSE:BETA: 3.81
As of today (2024-06-06), Beta Drugs's stock price is ₹1190.00.
Beta Drugs's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ₹307.60. Therefore, Beta Drugs's PS Ratio for today is 3.87.
Beta Drugs EV-to-Revenue Historical Data
The historical data trend for Beta Drugs's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Beta Drugs's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Drugs's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Beta Drugs's EV-to-Revenue falls into.
Beta Drugs's current Enterprise Value is ₹11,264 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Beta Drugs's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ₹2,957 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Drugs's share price for today is ₹1190.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Mar. 2024 was ₹307.60.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Drugs EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Beta Drugs's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports it to other countries of which key revenue is derived from the sales made in India.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NSE:BETA has been successfully added to your 